-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on AbbVie, Raises Price Target to $216

Benzinga·04/29/2025 12:18:21
Listen to the news
Guggenheim analyst Vamil Divan maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $214 to $216.